anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The risk of cancer is higher in patients with asthma compared to those with allergic rhinitis for many types of cancer, except for certain cancers where a contrasting pattern is observed. This study offers a potential explanation for these observations, proposing that the premalignant levels of circulating transforming growth factor-β (TGF-β), IL-1β, and IL-6 as well as the reactivity of the TGF-β/Smad signaling pathway at the specific cancer site, are crucial factors contributing to the observed disparities. Circulating TGF-β, IL- β and IL-6 levels also help clarify why asthma is positively associated with obesity, Type 2 diabetes, hypertension, and insulin resistance, whereas allergic rhinitis is negatively linked to these conditions. Furthermore, TGF-β/Smad pathway reactivity explains the dual impact of obesity, increasing the risk of certain types of cancer while offering protection against other types of cancer. It is suggested that the association of asthma with cancer and metabolic dysregulations is primarily linked to the subtype of neutrophilic asthma. A binary classification of TGF-β activity as either high (in the presence of IL-1β and IL-6) or low (in the presence or absence of IL-1β and IL-6) is proposed to differentiate between allergy patients prone to cancer and metabolic dysregulations and those less prone. Glycolysis and oxidative phosphorylation, the two major metabolic pathways utilized by cells for energy exploitation, potentially underlie this dichotomous classification by reprogramming metabolic pathways in immune cells.
Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
Patients with advanced/metastatic non-small cell lung cancer (NSCLC) in Greece treated with afatinib. Patients were treated as per the routine medical practice in terms of visit frequency, types of assessments performed and with adherence to the local prescribing requirements for afatinib. Patients were observed in the context of the study until the end of study participation, defined as a maximum of 48 months after afatinib treatment initiation or until disease progression, death, withdrawal of consent, unacceptable toxicity, study completion or physician's decision whichever occurred earlier.
The invention discloses an external pure Chinese medicine preparation for treating skin diseases. The external pure Chinese medicine preparation comprises the following compositions in parts by weight: 10-30 parts of propolis, 5-15 parts of Chinese gallnut, 5-15 parts of fructus schisandrae, 5-15 parts of radix stemonae, 5-15 parts of ailanthus glue, 5-15 parts of Chinese scholar tree glue, 5-15 parts of kuh-seng, 5-15 parts of benzoic acid and 10-20 parts of broom cypress fruit. The preparation can be prepared into spray, medicine solution or ointment. When the spray is prepared, the matrix material is alcohol or water; and when liquid solution or ointment is prepared, the matrix material is pine oil. The Chinese medicine raw materials in this invention are all in full accord, and the preparation has the functions of killing parasites, resisting virus, relieving itching and detoxifying, has the advantages of notable effect, good curative effect, short treating period, cheap and available raw material and no toxic side effect, and is convenient for use. In 56 clinical cases of various skin diseases, 24 cases are male patients and 32 cases female, aged from 3-62 years old, and the total effective rate of the preparation is 100%, and the cure rate is 94.6%.
INTRODUCTION: The aim of this study was to evaluate the features and benefits of different geriatric screening tools for enhancing the perioperative care of patients who undergo elective cancer surgery using cluster analysis.
METHODS: This study was a retrospective, observational analysis of 1,019 consecutive patients who had elective major cancer surgery in the urology department of our hospital from October 2019 to January 2023. Before the surgery, a trained nurse screened the patients using six tools: Eastern Clinical Oncology Group performance status (ECOG-PS), flemish version of the triage risk screening tool (fTRST), geriatric-8 (G8), instrumental activities of daily living, patient health questionnaire-2 (PHQ-2), and simple questionnaire to rapidly diagnose sarcopenia (SARC-F). The study grouped the patients into four clusters based on their scores on these tools and compared their outcomes after the surgery. The outcomes included overall survival, ambulation failure, delirium, and severe complications. The study also examined how each screening tool was associated with the outcomes.
RESULTS: Based on their clinical data and screening results, we classified the patients into four groups: Healthy (73%), Depressive (11%), Intermediate (11%), and Unhealthy (5%). The Unhealthy group had the worst outcomes in overall survival (OS), ambulation failure, and delirium, followed by the Intermediate group. In addition, fTRST and SARC-F emerged as significant predictors of OS; ECOG-PS, fTRST, G8, and SARC-F of ambulation failure; ECOG-PS, fTRST, and G8 of delirium; and G8 of severe complications.
CONCLUSION: Various geriatric screening tools were found to have the potential to forecast diverse postoperative outcomes.
A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds may be prepared as additives to pharmaceutical and cosmetic compositions, and in personal care products such as antiperspirants. In a particular embodiment extends to an antiperspirant product containing a skin darkening inhibitory amount of a compound of the invention. Also, the present skin darkening compounds may be prepared in combination with each other. The compounds, compositions and formulations of the invention may be used for the prevention of the onset or progression of conditions characterized by unwanted skin darkening, including those that may be causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.
The present invention relates to a medical device suitable for being inserted into the lumen of an anatomic structure of a subject, said medical device comprising means for administration of TRPC6 inhibitor, wherein said means comprises the TRPC6 inhibitor. The present invention further concerns a method of manufacturing a medical device suitable for being inserted into the lumen of an anatomic structure of a subject. Also, the invention relates to a TRPC6 inhibitor for use in the treatment or prevention of a disease associated with neointimal hyperplasia associated with the migration of smooth muscular cells. The invention also relates to a method of treating or preventing a disease associated with neointimal hyperplasia, said method comprising administering a TRPC6 inhibitor to a subject in need thereof. Also envisaged is a method of inhibiting migration of smooth muscle cells. The invention additionally relates to an in vitro test kit comprising: (a) small muscle cells (SMCs); (b) a surface suitable for SMC cultivation coated with a TRPC6 inhibitor. Also concerned is a pharmaceutical composition comprising a TRPC6 inhibitor and a pharmaceutically acceptable carrier.
The invention discloses an anti-aging gene recombinant small molecule polypeptide MT-1, a preparation method and application thereof, and belongs to the technical field of genetic engineering. The small molecular polypeptide MT-1 of the invention utilizes the design based on the new short peptide sequences of the type I and type III collagens to realize high-efficiency expression and purification in the escherichia coli, thereby effectively reducing the production cost. MT-1 can improve collagen quality, reduce immunogenicity, enhance solubility and expression quantity of recombinant protein, and is similar to natural human protein characteristics. The polypeptide has the advantages of obvious anti-aging effect, capability of reducing the aging level of fibroblast, regulating and controlling the cell cycle, preventing abnormal stagnation, promoting the normal proliferation of cells, and great application potential in the treatment of skin aging and age-related diseases. Has good industrialization application value and prospect. The preparation method provided by the invention is safe and efficient, high in production efficiency, low in production cost and wide in short application prospect.
This review will try to elucidate the interconnected pathophysiology of sarcopenia and type 2 diabetes (T2D) and will try to identify a common pathway to explain their development. To this end, the PubMed and Scopus databases were searched for articles published about the underlying pathophysiology, diagnosis and treatment of both sarcopenia and T2D. The medical subject heading (MeSH) terms 'sarcopenia' AND 'diabetes mellitus' AND ('physiopathology' OR 'diagnosis' OR 'therapeutics' OR 'aetiology' OR 'causality') were used. After screening, 32 papers were included. It was evident that sarcopenia and T2D share multiple pathophysiological mechanisms. Common changes in muscle architecture consist of a shift in myocyte composition, increased myosteatosis and a decreased capacity for muscle regeneration. Further, both diseases are linked to an imbalance in myokine and sex hormone production. Chronic low-grade inflammation and increased levels of oxidative stress are also known pathophysiological contributors. In the future, research efforts should be directed towards discovering common checkpoints in the development of T2D and sarcopenia as possible shared therapeutic targets for both diseases. Current treatment for T2D with biguanides, incretins and insulin may already convey a protective effect on the development of sarcopenia. Furthermore, attention should be given to early diagnosis of sarcopenia within the population of people with T2D, given the sizeable physical and medical burden it encompasses. A combination of simple diagnostic techniques could be used at regular diabetes check-ups to identify sarcopenia at an early stage and start lifestyle modifications and treatment as soon as possible.
Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
The glycosides of resorufin derivatives have the general formulae Ia and Ib <IMAGE> in which R<1> is hydrogen, R<2>, R<3> and R<5>, which can be identical or different, are hydrogen, halogen or a lower alkyl group, R<4> and R<6>, which can be identical or different, are hydrogen, halogen, a cyano, lower alkyl, lower alkoxy, carboxyl, lower alkoxycarbonyl, carboxy-lower alkyl, lower alkoxycarbonyl-lower alkyl or an optionally mono- or disubstituted carboxamide group or the group  -COO-(CH2CH2O)n-R<7> in which R<7> is hydrogen or a lower alkyl group and n is an integer from 1 to 4, where R<6> can additionally be a sulphonyl or nitro group, and Y is a nitrogen or the group NO. These compounds are particularly suitable as chromogenic and fluorogenic substrates for determining the activity of corresponding glycosidases or oligosaccharide-cleaving enzymes. The glycosides are obtained by reacting resorufin derivatives with a mono- or oligosaccharide or a 1-halogeno derivative thereof, whose hydroxyl groups are substituted by customary protective groups. This initially results in per-O-substituted glycosides, which can be converted into the claimed compounds by elimination of the protective groups. The glycosides are used as chromogenic and fluorogenic substrates in diagnostic agents for detecting glycosidases or oligosaccharide-cleaving enzymes. The resorufin derivatives employed as starting materials in the preparation of the compounds are also claimed.
Liquid water-soluble alkylene oxide addition products are prepared by condensing propylene oxide with addition products of ethylene oxide and aliphatic or alicyclic compounds containing at least 8 carbon atoms containing replaceable hydrogen atoms linked via oxygen, sulphur, or nitrogen; the addition products containing 5-20 mols of ethylene oxide per mol of aliphatic compound and the ratio of propylene oxide to ethylene oxide being 0.4 to 2. Compounds specified include alcohols, amines, mercaptans, carboxylic acids, sulphonic acids and acid amides.  Normally 0.5-1.5 mols of ethylene oxide are added per carbon atom present in the replaceable hydrogen containing compound. In Example 1, 1 mol of a C12-C14 fatty alcohol mixture is condensed with 9 mols of ethylene oxide at 120-148 DEG C. with sodium methylate present. 1 mol of this addition product is condensed with 10 mols of propylene oxide in the presence of sodium methylate at 125-144 DEG C. In Examples 2-7, under similar conditions, the following compounds are used:  a mixture of lauryl and myristyl alcohols, coconut fatty acid monoethanolamide, coconut fatty acid diethanolamide, coconut oil amines, lauric acid and coconut fatty acids.  The molar ratio of propylene to ethylene oxide used in these examples varies between 0.4 and 1.1, the initial adducts containing about 1 mole ethylene oxide.ALSO:Liquid water-soluble alkylene oxide addition products are prepared by condensing propylene oxide with addition products of ethylene oxide and aliphatic or alicyclic compounds containing at least 8 carbon atoms with replaceable hydrogen atoms linked via oxygen, sulphur or nitrogen; the addition products containing 5-20 mols of ethylene oxide per mol of aliphatic compound and the ratio of propylene oxide to ethylene oxide being 0.4 to 2.  Compounds specified include alcohols, amines, mercaptans, carboxylic acids, sulphonic acids and acid amides.  Normally 0.5-1.5 moles of ethylene oxide are added per carbon atom present in the replaceable hydrogen containing compound. In Example 1, 1 mol of a C12-C14 fatty alcohol mixture is condensed with 9 mols of ethylene oxide at 120-148 DEG C. with sodium methylate present. 1 mol of this addition product is condensed with 10 mols of propylene oxide in the presence of sodium methylate at 125-144 DEG C. In Examples 2-7, using similar conditions, the following compounds are used:-a mixture of lauryl and myristyl alcohols, coconut fatty acid mono-ethanolamide, coconut fatty acid diethanolamide, coconut oil amines, lauric acid and coconut fatty acids; and higher polymers are formed.  The molar ratio of propylene to ethylene oxide used in the examples varies between 0.4 and 1.1.
Sunscreen products that do not require the use of organic, ultraviolet-absorbing agents are provided. Effective protection of the skin from ultraviolet light is attained by increasing the amounts of titanium dioxide and zinc oxide. To mask the excessive whiteness that would otherwise result from the oxides, the sunscreen products contain multilayer-type encapsulations containing pigments. Before use, the pigments are enveloped in capsules that muffle the pigments' color. When the sunscreen product is applied to the skin, the capsules break and the pigments are released to counter the excessive whiteness due to titanium dioxide and zinc oxide. Sunscreen product precursors, from which these sunscreen products can be generated by stirring, are also provided. A sunscreen product package contains the sunscreen product precursor and a stirring ball. A method of ultraviolet protection is provided by shaking the sunscreen product package and applying the sunscreen product thus generated to the skin.
Participants will view emotional sequences composed of four emotional images. They will be asked to indicate whether the total duration of positive or negative emotional events was longer, by responding with a button press to a contextual cue defining the relevant action (Left vs Right button). The amount of temporal evidence in favor of one valence in a 12-s sequence is varied orthogonally with respect to the (predominant) emotional valence by varying individual picture presentation times. Participants will undergo one fMRI session and 3 TMS+fMRI sessions (2 of the TMS sessions target prefrontal (PFC) sites, and 1 targets a non-PFC control site).
PURPOSE: To obtain a composition capable of exhibiting effect of far-infrared of 8-24μm irradiated nearly at the body temperature by compounding ash of animals or plants. CONSTITUTION: This far-infrared irradiator is obtained by burning animals or plants at 725-900 deg.C for 12-6hr to completely remove carbon and reduce to ash and homogenizing the sizes of particles of the obtained ash to pass at least a 200-mesh sieve. The obtained ash can irradiate far-infrared having wave lengths of 8-12μm at the body temperature of a human with the radiation ratio of 80-95%. The far-infrared irradiator is obtained by the following process. Animals or plants are burned at 900-1500 deg.C to completely remove carbon, the obtained ash is heated up to melt and further heated at least for 30 min at lowest 900 deg.C. After the heating, the ash is rapidly cooled in water to make frit. Alternatively, the ash is cooled at standing and pulverized to powder passing at least a 200mesh sieve after the heating.  The objective far-infrared irradiating composition is obtained by mixing the obtained far-infrared irradiator to a paint, resin, paper, cloth, health product, ointment, poultice, cosmetic or medical pack, container, or ceramic.
Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see OVERDOSAGE]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of hydrocodone bitartrate and acetaminophen tablets, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy with and following dosage increases of hydrocodone bitartrate and acetaminophen tablets.

To reduce the risk of respiratory depression, proper dosing and titration of hydrocodone bitartrate and acetaminophen tablets are essential [see DOSAGE AND ADMINISTRATION].  Overestimating the hydrocodone bitartrate and acetaminophen tablets dosage when converting patients from another opioid product can result in a fatal overdose.

Accidental ingestion of hydrocodone bitartrate and acetaminophen tablets, especially by children, can result in respiratory depression and death due to an overdose of hydrocodone bitartrate and acetaminophen tablets.

Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper [see DOSAGE AND ADMINISTRATION].
The present invention provides process of preparing recombinant staphylococcus aureus enterotoxin O, as one kind of superantigen with the amino acid sequence as shown in SEQ ID No. 1. The present invention constructs one kind of recombinant plasmid for expression staphylococcus aureus enterotoxin O via recombining pGEX-4T-1 and the polynucleotide sequence of SEQ ID No. 1, and obtains initial fusion GST-SEO protein accounting for 15-25 % of total bacterial protein content. The present invention utilizes the recombinant staphylococcus aureus enterotoxin O with superantigen activity in promoting extracorporeal spleen lymphopoiesis and inhibiting extracorporeal tumor cell growth. It is proved that the recombinant staphylococcus aureus enterotoxin O has superantigen activity similar to that of SEC. The present invention is suitable for use in preparing high purity enterotoxin with superantigen activity and developing superantigen preparation.
To reconstitute solution, add 1 mL of diluent per mg of remifentanil. Shake well to dissolve. When reconstituted as directed, the solution contains approximately 1 mg of remifentanil activity per 1 mL.

  * Remifentanil Hydrochloride for injection should be diluted to a recommended final concentration of 20, 25, 50, or 250 mcg/mL prior to administration (see Table 5). Remifentanil Hydrochloride for injection should not be administered without dilution.



Continuous IV infusions of Remifentanil Hydrochloride for injection should be administered only by an infusion device. Infusion rates of Remifentanil Hydrochloride for injection can be individualized for each patient using Table 6:

When Remifentanil Hydrochloride for injection is used as an analgesic component of monitored analgesia care, a final concentration of 25 mcg/mL is recommended. When Remifentanil Hydrochloride for injection is used for pediatric patients 1 year of age and older, a final concentration of 20 or 25 mcg/mL is recommended. Table 7 is a guideline for milliliter-per-hour delivery for a solution of 20 mcg/mL with an infusion device.

Table 8 is a guideline for milliliter-per-hour delivery for a solution of 25 mcg/mL with an infusion device.

Table 9 is a guideline for milliliter-per-hour delivery for a solution of 50 mcg/mL with an infusion device.

Table 10 is a guideline for milliliter-per-hour delivery for a solution of 250 mcg/mL with an infusion device.